Norgine Secures Licensing Deal with Vir Biotechnology for Hepatitis Delta Treatment

Norgine Pharmaceuticals Limited has announced an exclusive agreement with Vir Biotechnology to commercialize a hepatitis delta treatment in Europe, Australia, and New Zealand. This deal marks a significant expansion of Norgine's hepatology portfolio. The treatment combines tobevibart, a monoclonal antibody, and elebsiran, a small interfering RNA, offering a novel approach to tackle chronic hepatitis delta (CHD).

The agreement includes a €55 million initial payment to Vir Biotechnology, with potential further payments up to €495 million based on regulatory and commercial milestones. Norgine will handle all commercialization activities and maintain marketing authorizations in the specified territories.

This collaboration underscores Norgine's commitment to addressing unmet medical needs in specialized care, with both companies aiming to enhance treatment accessibility and outcomes for CHD patients.